IP Library Granted Patent US 7,179,794
Granted Patent B2
US 7,179,794 · App. 10/330,381 · Granted Feb 20, 2007

Multivalent macrolide antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,794
App. No.
10/330,381
Granted
Feb 20, 2007
Kind
B2
Abstract

Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptoramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more proteins involved in ribosomal protein synthesis in the bacterium, which are useful in treating bacterial infections. The compounds adversely affect protein expression and have an antibacterial effect. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is macrolide antibiotic, aminoglycoside, lincosamide, oxazolidinone, streptogramin, tetracycline or other compound which binds to bacterial ribosomal RNA and/or one or more proteins involved in ribosomal protein synthesis in the bacterium.

Claims (30)

1. A compound of the formula:

L′-X′-L″

or a pharmaceutically-acceptable salt thereof;

wherein L′ is a moiety of the formula:

L″ is a moiety of the formula:

X′ has the formula:

—X a Z-(Y a -Z) m -Y b -Z-X a —

wherein

m is an integer of from 0 to 20;

X a at each separate occurrence is selected from the group consisting of —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR— and a covalent bond, where R is as defined below;

Z at each separate occurrence is selected from the group consisting of alkylene, substituted alkylene, cycloalkylene, substituted cylcoalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene, heterocyclene, and a covalent bond;

Y a and Y b at eaeh separate occurrence are selected from the group consisting of —C(O)NR′—, —NR′C(O)—, —NR′C(O)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—, —NR′—C(O)O—, —P(O)(OR′)—O—, —S(O) n CR′R″—, —S(O) n NR′—, —S—S— and a covalent bond; where n is 0, 1 or 2 and R, R′ and R″ at each separate occurrence are selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic.

2. The compound of claim 1 , wherein L′ is formula (i).

3. The compound of claim 1 , where L′ is formula (ii).

4. The compound of claim 1 , wherein L″ is formula (iii).

5. The compound of claim 1 , wherein L″ is formula (iv).

6. A compound of the formula:

L′-X′-L″

or a pharmaceutically-acceptable salt thereof;

wherein L′ is a moiety of the formula:

L″ is a moiety of the formula:

X′ has the formula:

—X a -Z-(Y a -Z) m -Y b -Z-X a —

wherein

m is an integer of from 0 to 20;

X a at each separate occurrence is selected from the group consisting of —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR— and a covalent bond, where R is as defined below;

Z at each separate occurrence is selected from the group consisting of alkylene, substituted alkylene, cycloalkylene, substituted cylcoalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene, heterocyclene, and a covalent bond;

Y a and Y b at each separate occurrence are selected from the group consisting of —C(O)NR′—, —NR′C(O)—, —NR′C(O)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—, —NR′—C(O)—O—, —P(O)(OR′)—O—, —S(O) n CR′R″—, —S(O) n —NR′—, —S—S— and a covalent bond; where n is 0, 1 or 2; and R, R′ and R″ at each separate occurrence are selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any of claims 1 to 6 .

8. A method of treating a bacterial infection in a patient, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 7 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033162/0629 →